Hopkins - MBA Trivia: COVID oral pill

Two years ago, two anti-COVID19 oral pills are ready for use now, namely Molnupiravir from Merck and Paxlovid from Pfizer.

Merck’s Molnupiravir has been approved for emergency use in the UK for the treatment of patients with mild to moderate Covid19 and those at risk of severe illness, including those with obesity, elderly, diabetes or heart disease. The results of clinical trials indicate that the new drug can reduce the risk of hospitalization or death by about half. Paxlovid is developed by Pfizer. Its clinical results show that it can even reduce the risk of hospitalization or death by 85%-89%.

At present, Merck announced its application has been submitted to the U.S. Food and Drug Administration (FDA). Both new pills can effectively fight against variant viruses such as Delta, Gamma, and Mu, and the viruses are also difficult to develop resistance to them. However, it is still unknown when the pandemic will end.

News & Events

Hopkins News: UNI MBA Graduation Ceremony 2018 (Hong Kong) - More Photos
UNI MBA Graduation Ceremony is held at the W Hotel on July 8, 2018 . Can’t be happier to share our graduates’ happiness of graduating …
Hopkins MBA News: 2018 Presidential Reception in Shanghai
Extending the network! UNI MBA cocktail reception in Shanghai on July 15 following the one in Hong Kong. Stunning view from Hu’s Penthouse, great food …
Accounting professor receives award for going

UNI Professor of Accounting Gerald Smith was honored with a 2015 UNI Above and Beyond Award from the Northern Iowa Student Government and Center for …

Hopkins Training & Education Group
31-33, 1/F, Tower 1, South Seas Center, 75 Mody Road, TST East, Hong Kong
Fax: +852 2332-2390
Whatsapp: +852 9840-8977

Copyright © 2020 Hopkins Training & Education Group
Privacy Policy · Terms & Conditions
Disclaimer: It is a matter of discretion for individual employers to recognize any qualifications to which these courses may lead.